Organization
Amgen, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Amgen, Inc.
... Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), ...
... Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, ...
... Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has ...
... 21-year-old Colombian rider, defended his lead from yesterday to claim the 2018 Amgen Tour of California championship by the second largest margin in race history, ...
... patients abandon them because they don’t help much or cause serious side effects.Amgen Inc. of Thousand Oaks, California, and Swiss drug giant Novartis AG developed ...
... the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a device similar to an ...
... abandon them because they don't help much or cause serious side effects. Amgen Inc. of Thousand Oaks, California, and Swiss drug giant Novartis AG developed ...
... engineered to increase muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. ("Amgen") to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil ...
... the expanded portfolio, Elliott Levy, MD, Senior Vice President, Global Development, at Amgen, and Chair of the Board for TransCelerate, stated, "Following a landscape assessment ...
... Led ZymoGenetics' sale to Bristol-Myers SquibbMember of Immunex Board when acquired by Amgen and part of integration teamPlayed a role in development of novel drugs ...
Subscribe now for full coverage on Amgen, Inc.
Start My Free Trial